CompletedNCT05727540Updated Sep 24, 2026

The Cohort Study of Uveitis Patients

An observational study in Uveitis, sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University. Completed at 1 site in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University · Observational

Study type: Observational
Model: Cohort
Time perspective: Prospective
Enrollment: 300
Ages: 18 Years to 90 Years
Sex: All

Study summary

This study intends to explore the epidemiology, pathogenesis, clinical manifestations, diagnosis and treatment of uveitis. This is a cohort study. The outcome of the study is the activity of inflammation and visual prognosis. The purpose of this study is to determine the optimal diagnosis and treatment scheme for uveitis patients based on real-world data.

Conditions studied

Uveitis

Browse trials for

Uveitis 299

In context

Uveitis

299 studies on the registry are indexed under Uveitis; 32 are open to participants now.

This study's enrollment of 300 is above the median of 107 across 104 observational studies indexed under Uveitis.

Browse Uveitis studies →

Lead sponsor

Zhongshan Ophthalmic Center, Sun Yat-sen University is the lead sponsor of 164 studies on the registry; 80 are open to participants now.

Browse Zhongshan Ophthalmic Center, Sun Yat-sen University studies →

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years to 90 Years
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Probability sample

Study population

The study population are adult uveitis patients.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The diagnosis is uveitis; The agreement of enrolling this study;

Exclusion criteria

Exclusion Criteria:

Uveitis during the first month after any intraocular surgery; \<18 years; pregnant and lactating women; other conditions are unsuitable for participation in this study by the investigator such as mental abnormalities.

Study design

Observational model: Cohort
Time perspective: Prospective
Enrollment: 300 participants (actual)
Patient registry: No

Groups and cohorts

Noninfectious uveitis
Infectious uveitis

What researchers measure

Primary outcomes

The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
activity of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
Time frame: 12 months post-treatment
The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions
inflammatory chorioretinal and/or inflammatory retinal vascular lesions were evaluated by fundus fluorescein angiography and indocyanine green angiography
Time frame: 12 months post-treatment

Secondary outcomes

Best corrected visual acuity
Best corrected visual acuity
Time frame: 1 month post-treatment
Best corrected visual acuity
Best corrected visual acuity
Time frame: 3 months post-treatment
Best corrected visual acuity
Best corrected visual acuity
Time frame: 6 months post-treatment
Best corrected visual acuity
Best corrected visual acuity
Time frame: 12 months post-treatment
Best corrected visual acuity
Best corrected visual acuity
Time frame: 24 months post-treatment
Best corrected visual acuity
Best corrected visual acuity
Time frame: 36 months post-treatment
The number of intraocular pressure
The number of Intraocular pressure was examed by non-contact tonometer
Time frame: 1 month post-treatment
The number of intraocular pressure
The number of Intraocular pressure was examed by non-contact tonometer
Time frame: 3 months post-treatment
The number of intraocular pressure
The number of Intraocular pressure was examed by non-contact tonometer
Time frame: 6 months post-treatment
The number of Intraocular pressure
The number of Intraocular pressure was examed by non-contact tonometer
Time frame: 12 months post-treatment
The number of Intraocular pressure
The number of Intraocular pressure was examed by non-contact tonometer
Time frame: 24 months post-treatment
The number of Intraocular pressure
The number of Intraocular pressure was examed by non-contact tonometer
Time frame: 36 months post-treatment
Central retinal thickness
Central retinal thickness was evaluated by Optical Coherence Tomography
Time frame: 1 month post-treatment
Central retinal thickness
Central retinal thickness was evaluated by Optical Coherence Tomography
Time frame: 3 months post-treatment
Central retinal thickness
Central retinal thickness was evaluated by Optical Coherence Tomography
Time frame: 6 months post-treatment
Central retinal thickness
Central retinal thickness was evaluated by Optical Coherence Tomography
Time frame: 12 months post-treatment
Central retinal thickness
Central retinal thickness was evaluated by Optical Coherence Tomography
Time frame: 24 months post-treatment
Central retinal thickness
Central retinal thickness was evaluated by Optical Coherence Tomography
Time frame: 36 months post-treatment
The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
activity of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
Time frame: 1 month post-treatment
The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
activity of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
Time frame: 3 months post-treatment
The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
activity of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
Time frame: 6 months post-treatment
The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
activity of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
Time frame: 24 months post-treatment
The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
activity of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
Time frame: 36 months post-treatment
The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions
inflammatory chorioretinal and/or inflammatory retinal vascular lesions were evaluated by fundus fluorescein angiography and indocyanine green angiography
Time frame: 3 months post-treatment
The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions
inflammatory chorioretinal and/or inflammatory retinal vascular lesions were evaluated by fundus fluorescein angiography and indocyanine green angiography
Time frame: 6 months post-treatment
The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions
inflammatory chorioretinal and/or inflammatory retinal vascular lesions were evaluated by fundus fluorescein angiography and indocyanine green angiography
Time frame: 24 months post-treatment
The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions
inflammatory chorioretinal and/or inflammatory retinal vascular lesions were evaluated by fundus fluorescein angiography and indocyanine green angiography
Time frame: 36 months post-treatment

Study locations

1 site

Zhongshan Ophthalmic Center
Guangzhou, Guangdong, China

Timeline

Tracking since Sep 25, 2026

ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Mar 2026, 37 months.

Of 32 observational studies under Uveitis, half reached primary completion within 77 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 143. This study's 37 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered: Jan 11, 2023
First posted: Feb 14, 2023
StartActual: Feb 20, 2023
Primary completionActual: Mar 31, 2026
CompletionActual: May 31, 2026
Last update: Sep 24, 2026

What these dates mean

Start.: When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.: When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.: When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.: Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.

No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT05727540
Lead sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University
Responsible party: Sponsor
First posted: Feb 14, 2023
Start date: Feb 20, 2023
Primary completion: Mar 31, 2026
Completion: May 31, 2026
Last update: Sep 24, 2026

Oversight

FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Uveitis →

Other studies from this sponsor

Zhongshan Ophthalmic Center, Sun Yat-sen University →

Start the discussion